Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
James L. Trevaskis, Jonathan D. Roth(Rutgers, The State University of New Jersey), Elizabeth M. Brunt(Washington University in St. Louis), Peter S. Griffin, Brent A. Neuschwander‐Tetri(Saint Louis University), David G. Parkes(Amplyx Pharmaceuticals (United States)), Carrie S. Dolman(Amplyx Pharmaceuticals (United States)), James Napora, Mary Erickson(Intercept Pharmaceuticals (United States)), Carrie Wittmer(Amplyx Pharmaceuticals (United States))
American Journal of Physiology-Gastrointestinal and Liver Physiology
January 21, 2012
Cited by 278
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
|Hepatology|2003|2.1k
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
|Hepatology|2010|1.1k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k